论文部分内容阅读
欧洲共同体药品专卖委员会已正式批准了Cen-tocor公司的人体单克隆抗体Centoxin(HA-lA)。在批准前1个月,该公司发表了Centoxin的一些主要试验结果。在随后的几个月里,还将由各成员国分别对Centoxin进行进一步的批准。药品专卖委员会及12个成员国的代表推荐Cen-toxin用于治疗严重的血液感染,这些感染可导致败血性休克及死亡。据最近统计的数据,在欧洲共同体国家和美国每年有100万的败血症患者,并且其死亡率已达60%.据Centocor公司总经理说,欧洲共同体药品法规部门之所以促进Centoxin的批准,是因为它有潜力挽救上千人的生命。该品是世界上首次供医生使用的人体单克隆抗体,是10多年来在学术研究及使用突破性技术以攻克顽症方面的重要进展。药品专卖委员会推荐:服用单剂量100mg Cen-toxin用于治疗败血症和革兰氏阴性菌血症,特别用
The European Community Monopoly Commission has formally approved Cen-tocor’s human monoclonal antibody Centoxin (HA-1A). One month prior to approval, the company published some of the main results of Centoxin. In the subsequent months, Centoxin will be further approved by each member country separately. Drug monographs and representatives of 12 member countries recommend Cen-toxin for the treatment of severe bloodstream infections that can lead to septic shock and death. According to recent statistics, there are 1 million sepsis patients each year in the European Community and the United States with a mortality rate of 60%. According to Centocor’s general manager, the approval of Centoxin by the European Medicines Regulatory Department is due to It has the potential to save thousands of lives. The product is the first human monoclonal antibody to be used by doctors in the world and represents an important advance in academic research and the use of breakthrough technologies to overcome chronic stubbornness for more than a decade. Drug Monographs recommended: Taking a single dose of 100mg Cen-toxin for the treatment of sepsis and Gram-negative bacteremia, especially with